Sleep Research & Evidence

The NIH's National Center for Complementary and Integrative Health (NCCIH) states plainly that "there's not enough strong evidence on the effectiveness or safety of melatonin supplementation for chronic insomnia to recommend its use," and that cognitive behavioral therapy is the recommended first-line approach for chronic insomnia. Evidence is stronger for narrower, timing-related uses: studies on jet lag suggest melatonin may help, and a 2018 trial on delayed sleep-wake phase disorder found participants fell asleep "an average of 34 minutes earlier." Short-term use appears safe for most adults, with mild side effects (headache, dizziness, nausea, next-day sleepiness) reported. NCCIH also flags a real quality-control issue: independent testing found roughly a quarter of tested melatonin supplements contained undisclosed serotonin, underscoring why third-party-tested products and accurate labeling matter.

A 2025 systematic review and meta-analysis of L-theanine and sleep found measurable improvements in sleep onset time, daytime functioning, and subjective sleep quality across the pooled trials (dose range roughly 50–900 mg/day in the studies reviewed). The authors' own conclusion is carefully hedged: "the lack of studies on 'pure' L-theanine warrants further investigation," and more research is needed in people with diagnosed clinical insomnia specifically, since most existing trials involved generally healthy adults with mild sleep complaints.

5-HTP is a precursor the body converts into serotonin. Memorial Sloan Kettering's clinician-reviewed reference is direct about the gap: "Studies evaluating 5-HTP for insomnia are lacking." The one sleep-related benefit it does note is narrow — 5-HTP "may improve pediatric sleep terrors" in children, which doesn't generalize to adults using it for general sleep support. On safety, it lists nausea, vomiting, and diarrhea as common side effects, and flags a serious interaction risk: patients taking SSRIs, MAOIs, or tricyclic antidepressants "should avoid taking 5-HTP without the supervision of a physician due to the theoretical potential for serotonin syndrome, a serious condition." A specific drug interaction with the antibiotic linezolid carries the same risk.

Apigenin is the flavonoid most associated with chamomile's calming reputation, and research suggests it interacts with GABA receptors similarly to how benzodiazepines do, though far more mildly. The clearest human evidence comes from an NIH/NCCIH-funded trial (grant R01 AT005074) of standardized chamomile extract in adults with generalized anxiety disorder: in the acute, open-label phase, 99 of 172 participants (58%) met clinical response criteria after 8 weeks. A follow-up randomized phase testing whether continuing chamomile prevented relapse found a trend favoring chamomile that did not reach statistical significance. That's a meaningfully positive signal for a rigorously designed trial, but it's an anxiety outcome, not a sleep outcome, and it studied whole chamomile extract, not isolated apigenin — supplement-grade isolated apigenin has much less standalone human data. Lemon balm has a long history of traditional use for calm and sleep, but is supported mainly by small, often combination-ingredient trials rather than large standalone studies.